Immutep (IMMP) Receivables (2011 - 2026)
Immutep's (IMMP) quarterly Receivables came in at $6.7 million in Q2 2026, up 5.62% on a YoY basis from $6.3 million in Q2 2025, and down 72.32% quarter-over-quarter from $24.1 million in Q4 2025.
Analysis
Immutep (IMMP) Receivables (2011 - 2026) Analysis & Trends
Immutep (IMMP) has reported Receivables for 16 consecutive years, with $6.7 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Receivables rose 5.62% year-over-year to $6.7 million; the trailing twelve-month figure through Jun 2026 stood at $6.7 million (up 5.62% YoY), and the FY2026 full-year result was $6.7 million, up 5.62% from the prior year.
- Receivables retreated to $6.7 million in Q2 2026 per IMMP's latest filing, from $24.1 million in the prior quarter.
- Across five years, Receivables topped out at $24.1 million in Q4 2025 and bottomed at $3.3 million in Q4 2022.
- Historically, Receivables has averaged $7.2 million across 5 years, with a median of $5.3 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Receivables slumped 35.35% in 2022, then jumped 439.65% in 2025.
- Over 5 years, Receivables stood at $3.3 million in 2022, then climbed by 21.06% to $4.0 million in 2023, then climbed by 12.48% to $4.5 million in 2024, then surged by 439.65% to $24.1 million in 2025, then slumped by 72.32% to $6.7 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $6.7 million, $24.1 million, and $6.3 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Immutep | 51.68 Mn | 51.68 Mn | - | 6.68 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.68 Mn |
| Dec 31, 2025 | 24.11 Mn |
| Jun 30, 2025 | 6.32 Mn |
| Dec 31, 2024 | 4.47 Mn |
| Jun 30, 2024 | 4.84 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Jun 30, 2023 | 5.31 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Dec 31, 2021 | 5.08 Mn |
| Jun 30, 2021 | 4.72 Mn |
| Dec 31, 2020 | 3.88 Mn |
| Jun 30, 2020 | 2.16 Mn |
| Dec 31, 2019 | 3.24 Mn |
| Jun 30, 2019 | 3.64 Mn |
| Jun 30, 2018 | 2.60 Mn |
| Dec 31, 2017 | 2.92 Mn |
| Jun 30, 2017 | 1.65 Mn |
| Mar 31, 2017 | 1.77 Mn |
| Dec 31, 2016 | 1.60 Mn |